Procedures and cybernic treatment

TN Takashi Nakajima
YS Yoshiyuki Sankai
ST Shinjiro Takata
YK Yoko Kobayashi
YA Yoshihito Ando
MN Masanori Nakagawa
TS Toshio Saito
KS Kayoko Saito
CI Chiho Ishida
AT Akira Tamaoka
TS Takako Saotome
TI Tetsuo Ikai
HE Hisako Endo
KI Kazuhiro Ishii
MM Mitsuya Morita
TM Takashi Maeno
KK Kiyonobu Komai
TI Tetsuhiko Ikeda
YI Yuka Ishikawa
SM Shinichiro Maeshima
MA Masashi Aoki
MI Michiya Ito
TM Tatsuya Mima
TM Toshihiko Miura
JM Jun Matsuda
YK Yumiko Kawaguchi
TH Tomohiro Hayashi
MS Masahiro Shingu
HK Hiroaki Kawamoto
request Request a Protocol
ask Ask a question
Favorite

After providing informed consent, eligible patients were enrolled into the pre-observation period of the trial (Fig. 1), during which the patients wore HAL-HN01 to ensure proper functioning of the CVC and shoe sensors and were subsequently randomised to group A or B.

Treatment 1 (conventional control treatment) consisted of a 40-min walking session using only a dedicated hoist (All in One®, Ropox A/S, Denmark) (Fig. 2A). The hoist was used for safety, to prevent falls, and to facilitate the provision of any gait assistance needed by the medical staff. A single walking session comprised warming up, 20 to 30 min of walking exercise depending on the patient’s condition, a brief rest, and a period of cooling down. Treatment 2 (cybernic treatment intervention) also consisted of a 40-min walking session using a hoist, with HAL-HN01 applied to the lower limbs (Fig. 2B). For both the treatments 1 and 2, the patients in groups A and B completed the sessions in nine visits (days), up to four visits per week, over a 13-week allowance period. The alternate treatment of either treatment 2 or 1 was then completed (Fig. 1). A transfer period, from one to 3 weeks, was scheduled between the treatments 1 and 2 to prevent any interference between the treatments’ efficacies and adverse effects. At the end of this period, there was a 4-week post-observation period to observe the persistence of clinical efficacy and the occurrence of adverse events after treatment. The treatment efficacy was evaluated as the change rate in the measured outcomes as follows: from the first to the final session of treatment 1 (i.e., Visit (V) 4 and V13 for group A and V14 and V23 for group B), and from the first to the final session of treatment 2 (i.e., V14 and V23 for group A, and V4 and V13 for group B), as well as to the final session of the post-observation period (i.e., V24 for both groups).

Photographs showing the use of mobile hoist and HAL-HN01 in control and cybernic treatments. A Control treatment (treatment 1), patient in hoist only. B Cybernic treatment (treatment 2), patient in hoist + wearing HAL

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A